Work

A 104-week delayed-start analysis of PASADENA (Phase II study evaluating the safety and efficacy of prasinezumab in early Parkinson’s disease) (S16.008)

Year: 2022

Type: article

Source: Neurology

DOI: 10.1212/wnl.98.18_supplement.2606

Authors: Gennaro Pagano, Stefano Zanigni, Annabelle Monnet, Kirsten I. Taylor, Andrea Hahn, Kenneth Marek, Ron Postuma, Nicola Pavese, Fabrizio Stocchi, Tanya Simuni, Giulia D’Urso, Nathalie Pross, Michael Lindemann, Hanno Svoboda, Paulo Fontoura, Rachelle Doody, Geoffrey A. Kerchner, Azad Bonni, Tania Nikolcheva

Institutions: King's College London, F. Hoffmann-La Roche AG, Institute for Neurodegenerative Disorders, Montreal General Hospital, McGill University, Newcastle University, IRCCS San Raffaele Roma, Northwestern University

Language: English

Topic: Parkinson's Disease Mechanisms and Treatments

Subfield: Neurology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W4389366605

FWCI:

Cites:

Cited by:

Related to: 10